/24-7PressRelease/ - NEW YORK, NY, October 29, 2006 - For flu, there are proven treatments. The drugs Tamiflu and Relenza, both of which were licensed in 1999, can lessen the misery and shave a day or two off the duration of flu, but only if started within the first two days after symptoms start.
Each year flu viruses are being traced by the medical professionals that could circulate during the seasonal flu and then it is decided to go for certain flu vaccination. Oral antiviral drugs such as Rimantadine (Flumadine) and newer agents Tamiflu and Relenza appear to work to prevent flu viruses.
According to sources, the manufacturer of the prescription medication Tamiflu has declared that there will be ample supply of the medicine for the year 2006-2007 all across the U.S. pharmacies. This is going to be double the quantity held last year. On this occasion, the president and CEO of the company said "Physicians can be confident that Tamiflu will be readily and widely available to patients who need it for flu treatment and post-exposure prevention."
At the same time, manufacturer of the antiviral influenza treatment Zanamivir (active ingredient in Relenza ) has made an agreement with other pharmaceutical companies in other parts of the world to manufacture and sell the product. This has been done to expand available supplies of zanamivir in areas of the world that may be on the front line of a possible influenza pandemic.
Relenza is therefore approved in many markets for the effective treatment of Influenza A and B among children and adults as well as for prophylaxis.
Please do visit http://www.benzer11.com/relenza.html to know more about influenza flu medicines and approved treatments.
About Benzer11.com
Benzer11.com has a team of committed pharmacists who are quite professional for their principals and values and lead a team of branch colleagues within their community.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Olivia Andrews:Other Press Release Headlines:
